Catholic University Experience With Molecular Adsorbent Recycling System in Patients With Severe Liver Failure
| Autor: | G. Di Gioacchino, Anna Chiara Piscaglia, Giovanni Gasbarrini, Maria Assunta Zocco, M. Santoro, Paolo Pola, L. Zileri Dal Verme, Marialuisa Novi, Roberto Flore, Angelo Santoliquido, R. Gaspari, Rodolfo Proietti, C. Di Campli, Paolo Tondi, Antonio Gasbarrini, Giuseppe Merra |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Hepatorenal Syndrome Bilirubin Catholic university experience Settore MED/12 - GASTROENTEROLOGIA Renal function Settore MED/09 Hemodiafiltration Gastroenterology chemistry.chemical_compound Hepatorenal syndrome Internal medicine Humans Medicine In patient Survival rate Hepatic encephalopathy Retrospective Studies Transplantation business.industry Liver failure Liver Failure Acute Middle Aged medicine.disease Liver Artificial Survival Analysis Surgery chemistry Hepatic Encephalopathy Chronic Disease Female Sorption Detoxification business Liver Failure |
| Zdroj: | Transplantation Proceedings. 37:2547-2550 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2005.06.048 |
| Popis: | Background and aim Molecular adsorbent recycling system (MARS) treatment is able to remove both hydrosoluble and small- and medium-sized lipophilic toxins. MARS plays an important role in modifying liver failure complications, such as hepatorenal syndrome and hepatic encephalopathy. We sought to evaluate the clinical efficacy and safety of a MARS device in a consecutive series of hepatic failure patients. Materials Twenty patients with acute liver failure, transplantation failure, or acute on chronic liver failure fulfilled the inclusion criteria of total bilirubin ≥10 mg/dL and at least one of the following: hepatic encephalopathy (HE) ≥II grade, hepatorenal syndrome (HRS) for chronic patients or total bilirubin ≥5 mg/dL and HE ≥I grade for acute patients. Results MARS was able to reduce cholestatic parameters and improve neurologic status and renal function parameters in all treated patients. We also observed an improvement in the 3-month survival rate compared to the expected outcome in patients with MELD scores between 20 and 29, as well as 30 and 39. Conclusions Based on these results, we confirm the safety and clinical efficacy of MARS treatment, with the best results in patients with MELD score of 20 to 29. Further studies are necessary to confirm whether this treatment is able to modify patient outcomes and prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect